EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer.

For patients with metastatic hormone-sensitive prostate cancer who achieve deep prostate-specific antigen responses with androgen deprivation therapy plus an androgen receptor pathway inhibitor, continuous treatment until progression may not be necessary. EORTC 2238 tests whether an intermittent strategy can safely reduce toxicity, improve quality of life, and lessen health care resource use.